Ikena Oncology

Ikena Oncology, Inc. is a clinical stage biotechnology company. It discovers and develops patient directed, biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412 and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed and biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412, and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.

Advancement across Company's pipeline towards regulatory and data milestones Advancement across Company's pipeline towards regulatory and data milestones

Ikena Oncology Reports Second Quarter 2022 Financial Results and Provides a Corporate Update

BOSTON, July 06, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that Mark Manfredi, Ph.D., Chief Executive Officer of Ikena, will participate in a panel discussion at the William Blair Biotech Focus Conference, taking place Wednesday, July 13, 2022 in New York, NY. Management will also be conducting one-on-one investor meetings at the conference.

Ikena Oncology to Participate in the William Blair Biotech Focus Conference 2022

BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for IK-930, the Company's novel TEAD inhibitor targeting the Hippo signaling pathway, in patients with unresectable NF2-deficient malignant pleural mesothelioma (MPM).

Ikena Oncology Receives FDA Fast Track Designation for Novel TEAD Inhibitor IK-930 to Treat Unresectable NF2-Deficient Mesothelioma

BOSTON, May 18, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will be presenting at the H.C. Wainwright Global Investment Conference, taking place May 23-26, 2022, and the Jefferies Global Healthcare Conference, taking place June 8-10, 2022.

Ikena Oncology to Participate in Spring 2022 Investor Conferences

IK-175 clinical trial combination expansion cohort in patients with urothelial carcinoma advanced to Stage 2 based on tolerability and preliminary anti-tumor activity

Ikena Oncology Reports First Quarter 2022 Financial Results and Provides a Corporate Update

Ikena Oncology (IKNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Is a Surprise Coming for Ikena Oncology (IKNA) This Earnings Season?

Angion Biomedica

Applied Therapeutics Inc

Bolt Biotherapeutics

Landos Biopharma

Let us take a look at some drug/biotech stocks, ANGN, APLT, BOLT, IKNA and LABP, which are poised to beat on first-quarter earnings.

5 Biotech Stocks Set to Outpace Q1 Earnings Estimates

WATERTOWN, Mass.--(BUSINESS WIRE)--Seismic Therapeutic, Inc., a biotechnology company advancing machine learning for immunology drug development, today announced the appointment of Maude Tessier, PhD, as Chief Business Officer. Dr. Tessier brings over 16 years of company building experience with a multi-disciplinary background in business development, corporate strategy, corporate communications, IP management, and portfolio and program management in public and private biotechnology, pharmaceut

Seismic Therapeutic Appoints Maude Tessier, PhD, as Chief Business Officer

Partnership will enable generation of tumor and biomarker-specific data to broaden Ikena's and VHIO's leadership in research, translational science, and development of targeted oncology therapies Partnership will enable generation of tumor and biomarker-specific data to broaden Ikena's and VHIO's leadership in research, translational science, and development of targeted oncology therapies

Ikena Oncology and Vall d'Hebron Institute of Oncology Announce Research & Development Collaboration

BOSTON, April 28, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that it will be presenting two trial-in-progress posters at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting. The presentations will include overviews of the clinical trials for Ikena's novel TEAD inhibitor, IK-930, and aryl hydrocarbon receptor (AHR) antagonist, IK-175. Both posters will be presented by the trials' investigators.

Ikena Oncology to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

Dr. Marango brings years of valued experience in oncology biopharma business, finance, and corporate relations & development Dr. Marango brings years of valued experience in oncology biopharma business, finance, and corporate relations & development

Ikena Appoints Jotin Marango, M.D., Ph.D., as Chief Financial Officer and Head of Corporate Development

Over $140M in capital raised in initial public offering in 2021; Cash runway through first half 2024

Ikena Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update

BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that it will participate in an oral presentation highlighting the company's novel TEAD inhibitor, IK-930, at the American Association for Cancer Research (AACR) 2022 Annual Meeting.

Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022 American Association for Cancer Research (AACR) Annual Meeting

BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that management will be participating in the Targeted Oncology Panel at the Cowen & Co 42nd Annual Health Care Conference, taking place March 7-9, 2022. The Company will also be holding investor meetings at the conference.

Ikena Oncology to Participate in Cowen 42nd Annual Health Care Conference

BOSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced the appointment of Richard Wooster, Ph.D., to its Board of Directors. Dr. Wooster brings more than 30 years of experience in oncology drug discovery and development and dissecting the genetics of cancer and will provide invaluable insight to Ikena as the Company progresses several programs to benefit patients with difficult-to-treat cancers.

Ikena Appoints Richard Wooster, Ph.D., to its Board of Directors

Dr. Zhang steps into the CSO role after spending more than five years at Ikena in research and development leadership

Ikena Appoints Michelle Zhang, Ph.D., Industry and Company Veteran, as Chief Scientific Officer

Data supports and describes the ongoing Phase 1a/b clinical trial of IK-175 as a single agent and in combination with nivolumab in advanced solid tumors

Ikena Oncology Presents Data at SITC 36th Annual Meeting Describing the Indication Selection Methodology, Translational Data, and Trial in Progress for IK-175

IND for IK-930 accepted by FDA; Phase 1 clinical trial expected to initiate in early 2022

Ikena Oncology Reports Third Quarter 2021 Financial Results and Corporate Update

BOSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that management will participate in several virtual investor conferences in November 2021.

Ikena Oncology to Participate in November 2021 Virtual Investor Conferences

Ikena expects to initiate its first-in-human phase 1 clinical trial in early 2022 in patients with solid tumors that harbor genetic alterations across the Hippo pathway Ikena expects to initiate its first-in-human phase 1 clinical trial in early 2022 in patients with solid tumors that harbor genetic alterations across the Hippo pathway

Ikena Oncology Announces FDA Acceptance of IND Application of Novel TEAD Inhibitor IK-930

BOSTON, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that the Company will present two virtual posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place October 7-10, 2021. Both presentations highlight the potential of inhibitors of the transcription factor TEAD, a key mediator of Hippo pathway signaling, in cancer treatment.

Ikena Oncology Presents Data at AACR-NCI-EORTC Virtual Conference Demonstrating Potential of TEAD Inhibitors in Cancer Treatment

BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that three abstracts highlighting the company's Aryl Hydrocarbon Receptor (AHR) antagonist program, with novel inhibitor IK-175, will be presented at the SITC 2021 Annual Meeting. IK-175 is an oral AHR antagonist designed to modulate the tumor microenvironment to increase both innate and adaptive immunity and is currently being studied in a Phase 1 clinical trial .

Ikena Oncology to Present a Trial-in-Progress Update, Translational Data, and Indication Selection Methodology for Novel AHR Inhibition Program at the 2021 Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting

BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways, today announced that management will participate in the virtual Morgan Stanley 19th Annual Global Healthcare Conference taking place on September 9-15, 2021, and the H.C. Wainwright 23rd Annual Global Investment Conference, taking place on September 13-15, 2021.

Ikena Oncology to Participate in September 2021 Virtual Investor Conferences

BOSTON, July 08, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced that Dr. Mark Manfredi, CEO of Ikena Oncology, will participate in a panel discussing next-generation approaches to targeted oncology at the upcoming virtual William Blair Biotech Focus Conference.

Ikena Oncology to Participate in Targeted Oncology Panel at the William Blair Biotech Focus Conference 2021

BOSTON--(BUSINESS WIRE)--Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced that management will participate in a fireside chat at the 2021 Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 2:00 p.m. ET. The fireside chat will be webcast live and can be accessed by visiting the Investors & Media section of the company's website at

News for Ikena Oncology Stock (IKNA)